1. Home
  2. VHC vs BTAI Comparison

VHC vs BTAI Comparison

Compare VHC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

N/A

Current Price

$16.50

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$1.56

Market Cap

35.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VHC
BTAI
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
35.6M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
VHC
BTAI
Price
$16.50
$1.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.33
AVG Volume (30 Days)
9.1K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
35.17
N/A
EPS
N/A
N/A
Revenue
$5,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$1.17
52 Week High
$29.00
$8.08

Technical Indicators

Market Signals
Indicator
VHC
BTAI
Relative Strength Index (RSI) 45.36 46.64
Support Level $15.94 $1.50
Resistance Level $18.09 $2.18
Average True Range (ATR) 1.43 0.14
MACD 0.22 0.00
Stochastic Oscillator 48.70 31.58

Price Performance

Historical Comparison
VHC
BTAI

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: